The stock of Can-Fite Biopharma Ltd ADR (AMEX: CANF) has decreased by -1.47 when compared to last closing price of 2.04. Despite this, the company has experienced a -6.07% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-16 that Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd.
Is It Worth Investing in Can-Fite Biopharma Ltd ADR (AMEX: CANF) Right Now?
Company’s 36-month beta value is 1.41.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CANF is 4.08M, and currently, short sellers hold a 4.17% ratio of that floaft. The average trading volume of CANF on September 24, 2024 was 100.44K shares.
CANF’s Market Performance
The stock of Can-Fite Biopharma Ltd ADR (CANF) has seen a -6.07% decrease in the past week, with a -15.19% drop in the past month, and a -29.22% fall in the past quarter. The volatility ratio for the week is 10.83%, and the volatility levels for the past 30 days are at 10.40% for CANF. The simple moving average for the last 20 days is -10.86% for CANF stock, with a simple moving average of -15.08% for the last 200 days.
Analysts’ Opinion of CANF
Many brokerage firms have already submitted their reports for CANF stocks, with Maxim Group repeating the rating for CANF by listing it as a “Buy.” The predicted price for CANF in the upcoming period, according to Maxim Group is $7 based on the research report published on August 11, 2017 of the previous year 2017.
Rodman & Renshaw gave a rating of “Buy” to CANF, setting the target price at $6 in the report published on August 29th of the previous year.
CANF Trading at -26.04% from the 50-Day Moving Average
After a stumble in the market that brought CANF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.14% of loss for the given period.
Volatility was left at 10.40%, however, over the last 30 days, the volatility rate increased by 10.83%, as shares sank -12.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.39% lower at present.
During the last 5 trading sessions, CANF fell by -1.40%, which changed the moving average for the period of 200-days by -8.66% in comparison to the 20-day moving average, which settled at $2.24. In addition, Can-Fite Biopharma Ltd ADR saw -8.63% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CANF
Current profitability levels for the company are sitting at:
- -11.03 for the present operating margin
- 1.0 for the gross margin
The net margin for Can-Fite Biopharma Ltd ADR stands at -10.06. The total capital return value is set at -1.03. Equity return is now at value -142.49, with -79.22 for asset returns.
Based on Can-Fite Biopharma Ltd ADR (CANF), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 2.38. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 50.59.
Currently, EBITDA for the company is -8.18 million with net debt to EBITDA at 0.52. When we switch over and look at the enterprise to sales, we see a ratio of 14.46. The receivables turnover for the company is 9.53for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
In a nutshell, Can-Fite Biopharma Ltd ADR (CANF) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
